Navigation Links
PrimeraDx Appoints David Heffelfinger as VP of Engineering and Systems Development
Date:12/1/2011

MANSFIELD, Mass., Dec. 1, 2011 /PRNewswire/ -- PrimeraDx today announced that David Heffelfinger has been appointed as Vice President of Engineering and Systems Development.

"It is an exciting time to join PrimeraDx.  The ICEPlex® System offers a glimpse into the future of molecular diagnostics, providing capabilities that are essential and timely," Commented Mr. Heffelfinger. 

"David brings to PrimeraDx extensive experience in the medical device industry and is a great addition to the executive team.  His knowledge and background in engineering and systems development, as well as his quality systems experience and six sigma training, are well aligned with the Company's strategy to provide next generation molecular diagnostics to the clinical laboratory market," said President and CEO Matthew McManus.

Mr. David Heffelfinger has held many Executive-level engineering positions within life science and medical device companies including Beckman Coulter, BD Biosciences, and Bio-Rad Laboratories as well as several startups and venture capital backed companies including Biometric Imaging, Alpha Innotech Corp, and Luminys Systems.  Dave was also a founder of his own company, Hyperspectra LLC.  He began his professional career at General Motors Research Laboratories in Warren, Michigan as an Applied Physicist.  He received his B.S. and M.S. in Physics from Wayne State University and an Executive MBA from Saint Mary's College in Moraga, California.  He holds 27 US and international patents in the fields of imaging, optics, bio-systems, and instrumentation.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis.  The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative, answers to the clinic.  The company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.  Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.  PrimeraDx's technology represents the next generation of quantitative PCR.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
2. Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team
3. CVS Caremark Appoints Kevin Murphy President of Accordant Business
4. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
5. Adeona Appoints Jeff Lucero Riley as Independent Chairman
6. Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
7. InterMune Appoints Angus C. Russell to Board of Directors
8. Volcano Corporation Appoints Leslie V. Norwalk and Dr. Eric J. Topol to Board of Directors
9. Vanda Pharmaceuticals Appoints Chief Commercial Officer
10. Cardica Appoints Christopher Littel VP, Sales and Marketing
11. S1 Pharmaceuticals Appoints Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to Its Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, a ... of Mark Weinberg , MD MBA as Chief Medical Officer. ... USA . ... Dr Weinberg has spent more than 17 years as ... pharma companies to micro-cap biotech. Over the course of his career, ...
(Date:1/19/2017)... -- The Global Therapy Partnering Terms and Agreements since ... and agreements entered into by the world,s leading healthcare ... deals by value - Deals listed by company A-Z, ... report provides understanding and access to the partnering deals ... companies. The report provides an analysis of partnering ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... System: an On-demand E-learning system for Clinical and Regulatory education for Physicians, ... based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. , ...
(Date:1/19/2017)... ... ... cold weather here, many people will have to clear snow with snow blowers or shovels ... but they can be dangerous when used incorrectly. That’s why Amica Insurance is ... of snow blowers:, , When removing wet snow or debris from ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media company ... Heart Association (AHA) to produce a three-part video series that uses humor to highlight ... of the launch of AHA’s Healthy For Good™ movement, which is designed to inspire ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish ... a condensed version of the clinic’s leading recovery program. , “We know ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... announced it recently provided a new $11,250,000 senior credit facility to Sunrise, Florida-based ... MB credit facility were used to facilitate a recapitalization of MedPro led by ...
Breaking Medicine News(10 mins):